Rasio utang jangka cendhak marang ekuitas: Chromocell Therapeutics (CHRO)
This price chart illustrates the financial standing of Chromocell Therapeutics (CHRO), where the indicator stands at 0.00. Management of this micro-cap company is developing non-opioid analgesics despite a limited budget. The business relies on the study of ion channels, building valuable intellectual capital for future licensing deals. The startup is currently focusing on preclinical research, planning to attract a strategic partner to commercialize its molecules.
Rincian metrik lan analitis perusahaan chromocell.com (CHRO)
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Chromocell Therapeutics|CHRO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Chromocell Therapeutics Corp.|CHRO - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Chromocell Therapeutics Corp|CHRO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Chromocell Therapeutics|Likuiditas cepet chromocell.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
Pambiji fundamental:CHRO Chromocell Therapeutics Corporation
This ratio assesses liquidity risk by comparing liabilities maturing within one year against equity, while the history of short-term debt relative to equity determines the company's reliance on quick loans, which is critical for Chromocell Therapeutics (CHRO), whose significant pricing power in the inelastic demand segment for non-opioid pain relief should ensure the stability of its financial structure.
Pesaing langsung
Utang jangka cendhak marang modal BIIB|NBIX - Kewajiban jangka cendhak marang modal|Regencell Bioscience - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal axsome.com AXSM|ACAD - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas denalitherapeutics.com (DNLI)|Utang jangka cendhak marang modal HRMY|BHVN (Biohaven Ltd) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Amylyx AMLX|Rasio tanggungan utang jangka cendhak marang modal TRVI|PRAX - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal anavex.com|CeriBell (CBLL) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang ekuitas Prothena Biosciences|Utang jangka cendhak marang ekuitas Alector Inc.|Kewajiban jangka cendhak marang modal Annexon Biosciences Inc. ANNX|Utang jangka cendhak marang modal OMER|Rasio utang jangka cendhak marang ekuitas neurogene.com NGNE|Utang jangka cendhak marang modal ACIU (AC Immune SA)|Voyager Therapeutics Inc (VYGR) - Kewajiban jangka cendhak marang modal|NMRA - Utang jangka cendhak marang ekuitas|SCLX: Utang jangka cendhak marang ekuitas|Tevogen Bio Holdings (TVGN) - Utang jangka cendhak marang ekuitas|ACOG (Alpha Cognition Inc.) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang ekuitas CGTX|IKT: Rasio tanggungan utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas SAVA (Cassava)|Rasio silihan jangka cendhak marang modal ASRT|Utang jangka cendhak marang modal COYA (Coya Therapeutics)|Rasio tanggungan utang jangka cendhak marang modal VTGN|Ovid Rx - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Acumen Pharmaceuticals Inc.|CervoMed Inc (CRVO) - Utang jangka cendhak marang ekuitas|Alterity Therapeutics Limited - Rasio tanggungan utang jangka cendhak marang modal|CLNN (Clene Inc) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal PepGen Corp|Utang jangka cendhak marang ekuitas Jupiter Neurosciences (JUNS)|RLMD: Kewajiban jangka cendhak marang ekuitas|Utang jangka cendhak marang modal ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Kewajiban jangka cendhak marang modal|AIFF: Rasio utang jangka cendhak marang ekuitas|KLTO - Utang jangka cendhak marang modal|NRSN (neurosense-tx.com) - Rasio utang jangka cendhak marang ekuitas|RVPH: Rasio silihan jangka cendhak marang modal|MTVA (MetaVia Inc.) - Utang jangka cendhak marang modal|NeurAxis Inc (NRXS) - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang modal HSDT|Rasio utang jangka cendhak marang ekuitas passagebio.com PASG|Utang jangka cendhak marang ekuitas Neuphoria Therapeutics NEUP|Koefisien utang jangka cendhak marang modal Minerva Neurosciences Inc (NERV)|Athira - Utang jangka cendhak marang modal|Addex (ADXN) - Rasio utang jangka cendhak marang ekuitas|ALZN: Utang jangka cendhak marang modal|Cyclerion Therapeutics, Inc. - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Protagenic Therapeutics Inc.|KTTA: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Cortigent, Inc. (CRGT)|ATXI - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Brainstorm Cell BCLI|CARA: Rasio utang jangka cendhak marang modal|Eliem - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Intra-Cellular Therapies|LBPH (Longboard Pharma) - Rasio utang jangka cendhak marang ekuitas|Marinus Pharma (MRNS) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas NKGen Biotech, Inc.|NRBO: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Sage Therapeutics (SAGE)|SNPX - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang modal TRVN (Trevena, Inc)|VIGL - Rasio utang jangka cendhak marang ekuitas|Anew Medical, Inc. - Utang jangka cendhak marang modal|Rasio tanggungan utang jangka cendhak marang modal CERE (cerevel.com)